Hot Melt Extruded Posaconazole-Based Amorphous Solid Dispersions-The Effect of Different Types of Polymers.
amorphous
amorphous polymers
amorphous solid dispersion
hot melt extrusion
physical stability
posaconazole
semi-crystalline polymers
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
28 Feb 2023
28 Feb 2023
Historique:
received:
02
02
2023
revised:
22
02
2023
accepted:
24
02
2023
medline:
30
3
2023
entrez:
29
3
2023
pubmed:
30
3
2023
Statut:
epublish
Résumé
Four model polymers, representing (i) amorphous homopolymers (Kollidon K30, K30), (ii) amorphous heteropolymers (Kollidon VA64, KVA), (iii) semi-crystalline homopolymers (Parteck MXP, PXP), and (iv) semi-crystalline heteropolymers (Kollicoat IR, KIR), were examined for their effectiveness in creating posaconazole-based amorphous solid dispersions (ASDs). Posaconazole (POS) is a triazole antifungal drug that has activity against Candida and Aspergillus species, belonging to class II of the biopharmaceutics classification system (BCS). This means that this active pharmaceutical ingredient (API) is characterized by solubility-limited bioavailability. Thus, one of the aims of its formulation as an ASD was to improve its aqueous solubility. Investigations were performed into how polymers affected the following characteristics: melting point depression of the API, miscibility and homogeneity with POS, improvement of the amorphous API's physical stability, melt viscosity (and associated with it, drug loading), extrudability, API content in the extrudate, long term physical stability of the amorphous POS in the binary drug-polymer system (in the form of the extrudate), solubility, and dissolution rate of hot melt extrusion (HME) systems. The obtained results led us to conclude that the physical stability of the POS-based system increases with the increasing amorphousness of the employed excipient. Copolymers, compared to homopolymers, display greater homogeneity of the investigated composition. However, the enhancement in aqueous solubility was significantly higher after utilizing the homopolymeric, compared to the copolymeric, excipients. Considering all of the investigated parameters, the most effective additive in the formation of a POS-based ASD is an amorphous homopolymer-K30.
Identifiants
pubmed: 36986660
pii: pharmaceutics15030799
doi: 10.3390/pharmaceutics15030799
pmc: PMC10056184
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : National Science Center
ID : 2018/31/B/ST8/01327
Références
Drug Deliv. 2020 Dec;27(1):110-127
pubmed: 31885288
Expert Opin Drug Deliv. 2011 May;8(5):693-703
pubmed: 21417781
J Pharm Sci. 2010 Sep;99(9):3787-806
pubmed: 20623696
Int J Pharm. 2018 Jan 15;535(1-2):68-85
pubmed: 29102700
Int J Pharm. 1999 Mar 15;179(2):179-207
pubmed: 10053213
Eur J Pharm Biopharm. 2019 Mar;136:231-239
pubmed: 30703545
Polymers (Basel). 2021 Aug 30;13(17):
pubmed: 34502962
Mol Pharm. 2015 Sep 8;12(9):3408-19
pubmed: 26214347
Materials (Basel). 2020 Nov 04;13(21):
pubmed: 33158192
Pharmacol Rev. 2013 Jan;65(1):315-499
pubmed: 23383426
Drug Dev Ind Pharm. 2017 May;43(5):797-811
pubmed: 27616147
Eur J Pharm Sci. 2022 Feb 1;169:106086
pubmed: 34861411
Mol Pharm. 2006 Nov-Dec;3(6):631-43
pubmed: 17140251
Pharmaceuticals (Basel). 2022 Jan 05;15(1):
pubmed: 35056125
Pharm Res. 2010 Dec;27(12):2704-14
pubmed: 20859662
Pharmaceutics. 2020 Oct 24;12(11):
pubmed: 33114382
J Pharm Pharmacol. 2010 Nov;62(11):1580-90
pubmed: 21072971
Drug Dev Ind Pharm. 2003 Aug;29(7):739-44
pubmed: 12906331
Eur J Pharm Sci. 2007 Mar;30(3-4):288-94
pubmed: 17204410
Adv Drug Deliv Rev. 2012 May 1;64(6):480-95
pubmed: 22265844
Pharmaceutics. 2019 Oct 14;11(10):
pubmed: 31614985
Acta Pharm Sin B. 2014 Feb;4(1):18-25
pubmed: 26579360
J Pharm Pharmacol. 2004 Dec;56(12):1527-35
pubmed: 15563759
Expert Opin Drug Deliv. 2007 Jul;4(4):403-16
pubmed: 17683253
Adv Drug Deliv Rev. 2012 Apr;64(5):396-421
pubmed: 21843564
Mol Pharm. 2017 Apr 3;14(4):1154-1168
pubmed: 28241116
Int J Mol Sci. 2022 Aug 22;23(16):
pubmed: 36012748
Pharm Res. 1995 Jun;12(6):799-806
pubmed: 7667182
J Pharm Sci. 2016 Sep;105(9):2527-2544
pubmed: 26886314
Pharmaceutics. 2022 Oct 16;14(10):
pubmed: 36297638
Mol Pharm. 2008 Nov-Dec;5(6):927-36
pubmed: 19434849
Eur J Pharm Biopharm. 2019 Oct;143:8-17
pubmed: 31398439
AAPS PharmSciTech. 2016 Feb;17(1):200-13
pubmed: 26729536
Expert Rev Clin Pharmacol. 2015 May;8(3):321-34
pubmed: 25916666
ISRN Pharm. 2012;2012:195727
pubmed: 22830056
J Control Release. 2016 Jul 28;234:41-8
pubmed: 27189134
Int J Pharm. 2019 Jan 30;555:124-134
pubmed: 30448311
Drug Dev Ind Pharm. 2007 Oct;33(10):1043-57
pubmed: 17963112
AAPS J. 2015 Nov;17(6):1317-26
pubmed: 26338234
Mol Pharm. 2019 Apr 1;16(4):1742-1750
pubmed: 30848603
Mol Pharm. 2014 Sep 2;11(9):3048-55
pubmed: 25105216
Int J Pharm. 2022 Mar 25;616:121538
pubmed: 35124119
Eur J Pharm Biopharm. 2019 Feb;135:1-12
pubmed: 30529295
Eur J Pharm Biopharm. 2011 May;78(1):125-33
pubmed: 21168491
Life Sci. 2022 Feb 15;291:120301
pubmed: 34999114
Int J Pharm. 2013 Aug 30;453(1):65-79
pubmed: 22569230
Acta Pharm Sin B. 2015 Sep;5(5):442-53
pubmed: 26579474
J Pharm Sci. 1997 Jan;86(1):1-12
pubmed: 9002452
Mol Pharm. 2017 Jan 3;14(1):157-171
pubmed: 28043133
J Pharm Pharmacol. 2014 Feb;66(2):148-66
pubmed: 24325738
Mol Pharm. 2019 Aug 5;16(8):3626-3635
pubmed: 31287704
J Pharm Sci. 2010 Jul;99(7):2941-7
pubmed: 20127825
Mol Pharm. 2021 Aug 2;18(8):3050-3062
pubmed: 34250800
Molecules. 2021 Jan 05;26(1):
pubmed: 33466393
J Pharm Sci. 2016 Jan;105(1):160-7
pubmed: 26852851
AAPS PharmSciTech. 2016 Feb;17(1):20-42
pubmed: 26159653
Pharmaceutics. 2018 Jul 11;10(3):
pubmed: 29997332
J Pharm Sci. 2020 Dec;109(12):3636-3644
pubmed: 32949563
Sci Rep. 2020 Oct 28;10(1):18535
pubmed: 33116200
Pharm Res. 2000 Apr;17(4):397-404
pubmed: 10870982
Adv Drug Deliv Rev. 2016 May 1;100:27-50
pubmed: 26705850
J Pharm Sci. 2019 Sep;108(9):3063-3073
pubmed: 31103788